BioCentury | May 23, 2019
Politics & Policy

Bipartisan HELP draft bill seeks to squeeze PBMs, enhance generic and biosimilar competition

The Senate health committee Thursday released bipartisan draft legislation, the Lower Health Care Costs Act of 2019 , that attempts to squeeze PBM profits out of the drug supply chain, eliminate tactics branded drug manufacturers use...
BioCentury | Sep 2, 2017
Strategy

Back to School 2017: Breach of contract

Merck & Co. Inc. Chairman and CEO Kenneth Frazier’s resignation in August from a White House advisory council was an act of principle, and a reminder that 30 years ago Merck was one of the...
BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Iron responsive element binding protein 2 (IREB2; IRP2; ACO3)

...Pulmonary disease INDICATION: Chronic obstructive pulmonary disease (COPD) Mouse studies suggest inhibiting IREB2 or mitochondrial iron...
...mitochondrial iron deposition could help treat COPD. In two mouse models of cigarette smoke-induced COPD, IREB2...
...include testing mitochondrial iron chelation in additional models of COPD. TARGET/MARKER/PATHWAY: Iron responsive element binding protein 2 (IREB2; IRP2 ; ACO3...
BioCentury | Aug 24, 2015
Emerging Company Profile

Transforming wellness

Arivale Inc. aims to build a consumer wellness business on top of systems biology work conducted by Lee Hood, using genetics and other personalized data in combination with coaching to improve an individual's health outcomes....
BioCentury | Mar 23, 2015
Strategy

Show me the value

At a time when industry is struggling mightily with how to demonstrate the value of its products to payers and patients and translate that value into pricing, The Medicines Co. could provide some lessons. The...
BioCentury | Nov 3, 2014
Clinical News

HA-Irinotecan: Phase III data

The double-blind, Australian Phase III ACO002 trial in 415 irinotecan-naive patients who failed previous therapy showed that HA-Irinotecan as part of FOLFIRI therapy as second- or third-line treatment missed the primary endpoint of improving median...
BioCentury | Aug 4, 2014
Strategy

Guest Commentary: Biopharma's echo chamber

Of the many reasons for business failure, not listening to customers is the king. And too many biopharmas today are walking around wearing earplugs. In the U.S., managers are dealing with a set of increasingly...
BioCentury | Jun 23, 2014
Clinical News

HA-Irinotecan: Phase III ongoing

Alchemia said it now expects to report top-line data from the double-blind, international Phase III ACO002 trial of HA-Irinotecan before the end of 3Q14. The company, which previously said it expected data this half, said...
BioCentury | Feb 1, 2014
Politics & Policy

CMS: half of Shared Savings ACOs saved money

According to data from CMS, only 54 of the 114 accountable care organizations (ACOs) enrolled in the Medicare Shared Savings Program generated $128 million in savings for the Medicare Trust Fund and had lower spending...
BioCentury | Jan 31, 2014
Politics & Policy

CMS reports interim savings for ACO programs

Two accountable care organization (ACO) programs that were created by the Affordable Care Act generated more than $380 million in savings in their first year, according to interim (see BioCentury, Sept. 2, 2013) . BC Staff...
Items per page:
1 - 10 of 29